Versuchen GOLD - Frei

Smartphone sector hits road to revival with budget models

Mint Chennai

|

February 18, 2025

Every time you buy a smartphone, the tech specs you get at a certain price level multiply from the previous buy. This percolation of high tech to lower-priced gadgets sparked a rush for budget smartphones priced below ₹20,000 in the past year, a trend that industry insiders expect to continue in 2025.

- Shouvik Das

Smartphone sector hits road to revival with budget models

The revival comes in the backdrop of a slowdown in sales of smartphones in recent years. Overall smartphone sales in India grew just 4% in 2024 year-on-year (y-o-y) after being stagnant the previous year, according to market researcher International Data Corp (IDC) India.

However, sales of phones priced at ₹20,000 and below sold 35% more in 2024 compared to 2023. Further, sales doubled y-o-y in 2024 for 5G-enabled smartphones priced under ₹20,000.

To be sure, 5G-enabled phones accounted for four out of every five smartphones sold in India last year, while almost one in every two 5G phones sold last year was from the budget segment.

Smartphone brands and sellers expect this trend would continue in 2025, reviving interest in one of the largest electronics categories in the country. Phones priced below ₹20,000 comprise the biggest revenue driver in an industry that generated nearly $40 billion in revenue last year—that's nearly 30% of the domestic electronics industry's annual revenue right now.

WEITERE GESCHICHTEN VON Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size